Vaccine Therapy in Non-Small Cell Lung Cancer

Miguel García-Pardo (1) , Teresa Gorria , Ines Malenica , Stéphanie Corgnac (2) , Cristina Teixidó , Laura Mezquita (3)

1 Princess Margaret Cancer Centre [Toronto, Canada]
2 INTIM - Immunologie intégrative des tumeurs et immunothérapie des cancers
3 University of Barcelona

Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as a new standard of care for multiple indications, including non-small cell lung cancer (NSCLC). However, prognosis for patients with lung cancer is still poor. Although immunotherapy is highly effective in some cases, not all patients experience significant or durable responses, and further strategies are needed to improve outcomes. Therapeutic cancer vaccines are designed to exploit the body’s immune system to activate long-lasting memory against tumor cells that ensure tumor regression, with minimal toxicity. A unique feature of cancer vaccines lies in their complementary approach to boost antitumor immunity that could potentially act synergistically with immune checkpoint inhibitors (ICIs). However, single-line immunization against tumor epitopes with vaccine-based therapeutics has been disappointingly unsuccessful, to date, in lung cancer. The high level of success of several recent vaccines against SARS-CoV-2 has highlighted the evolving advances in science and technology in the vaccines field, raising hope that this strategy can be successfully applied to cancer treatments. In this review, we describe the biology behind the cancer vaccines, and discuss current evidence for the different types of therapeutic cancer vaccines in NSCLC, including their mechanisms of action, current clinical development, and future strategies.

Domaines: Sciences du Vivant [q-bio]

Miguel García-Pardo, Teresa Gorria, Ines Malenica, Stéphanie Corgnac, Cristina Teixidó, et al.. Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines, 2022, 10 (5), pp.740. ⟨10.3390/vaccines10050740⟩. ⟨hal-04492800⟩